Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Ophthalmologie
Erschienen in: Die Ophthalmologie 12/2017

20.11.2017 | EBM | Leitlinien, Stellungnahmen und Empfehlungen

Leitlinie Nr. 24b der DOG und BVA

Nichtinfektiöse Uveitis posterior

verfasst von: Deutsche Ophthalmologische Gesellschaft, Berufsverband der Augenärzte Deutschlands e. V.

Erschienen in: Die Ophthalmologie | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Auszug

Leitlinien sind Orientierungshilfen im Sinne von „Handlungs- und Entscheidungskorridoren“, von denen in begründeten Fällen abgewichen werden kann oder sogar muss. Sie beschreiben, was Augenärzte für eine angemessene Patientenversorgung in der Praxis und Klinik für geboten halten. Dies entspricht nicht immer dem Leistungsniveau der gesetzlichen Krankenversicherung in Deutschland (s. Präambel, [11]). …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Adan A, Mesquida M, Llorenc V et al (2013) Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 251:2627–2632 (III)CrossRefPubMed
3.
Andrasch RH, Pirofsky B, Burns RP (1978) Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 96:247–251 (III)CrossRefPubMed
4.
Androudi S, Tsironi E, Kalogeropoulos C et al (2010) Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 117:1612–1616 (III)CrossRefPubMed
5.
6.
Artornsombudh P, Gevorgyan O, Payal A et al (2013) Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology 120:588–592 (III)CrossRefPubMed
7.
Baltatzis S, Tufail F, Yu EN et al (2003) Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110:1061–1065 (III)CrossRefPubMed
8.
Baughman RP, Lower EE, Bradley DA et al (2005) Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 128:1062–1047 (Ib)CrossRefPubMed
9.
Becker MD, Heiligenhaus A, Hudde T et al (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89:1254–1257 (III)CrossRefPubMedCentralPubMed
10.
BenEzra D, Cohen E, Chajek T et al (1988) Evaluation of conventional therapy versus cyclosporine A in Behçet’s syndrome. Transplant Proc 20:136–143 (Ib)PubMed
11.
12.
13.
14.
Callanan DG, Jaffe GJ, Martin DF et al (2008) Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 126(9):1191–1201 (Ib)CrossRefPubMed
15.
Calvo-Río V, Blanco R, Beltrán E et al (2014) Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 53:2223–2231 (Ib)CrossRef
16.
Cruz BA, Reis DD, Araujo CA, Minas Gerais Vasculitis Study Group (2007) Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int 27(III):1181–1183CrossRefPubMed
17.
Davatchi F, Shams H, Rezaipoor M et al (2010) Rituximab in tractable ocular lesions of Behcet’s disease: randomized single-blind control study (pilot study). Int J Rheum Dis 13:246–252CrossRefPubMed
18.
19.
de Vries J, Baarsma GS, Zaal MJ et al (1990) Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 74:344–349 (Ib)CrossRefPubMedCentralPubMed
20.
Deuter CM, Doycheva D, Stuebiger N, Zierhut M (2009) Mycophenolate sodium for immunosuppressive treatment in uveitis. Ocul Immunol Inflamm 17:415–419 (III)CrossRefPubMed
21.
Dick AD, Tundia N, Sorg R et al (2016) Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 123:655–662 (IIb)CrossRefPubMed
22.
23.
Doycheva D, Jägle H, Zierhut M et al (2015) Mycophenolic acid in the treatment of birdshot chorioretinopathy: long-term follow-up. Br J Ophthalmol 99:87–91 (III)CrossRefPubMed
24.
Dunn JP (2004) Review of immunosuppressive drug therapy in uveitis. Curr Opin Ophthalmol 15:293–298 (III)CrossRefPubMed
25.
26.
Esterberg E, Acharya NR (2012) Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect 2(1):21–28 (IV)CrossRefPubMed
27.
Engelhard SB, Patel V, Reddy AK (2015) Intermediate uveitis, posterior uveitis, and panuveitis in the Mid-Atlantic USA. Clin Ophthalmol 9:1549–1555 (III)CrossRefPubMedCentralPubMed
28.
Farvardin M, Afarid M, Mehryar M, Hosseini H (2010) Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 30:1530–1535 (III)CrossRefPubMed
29.
Fend F, Ferreri AJ, Coupland SE (2016) How we diagnose and treat vitreoretinal lymphoma. Br J Haematol 173:680–692 (III)CrossRefPubMed
30.
French Behçet Network, Vallet H, Riviere S, Sanna A et al (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun 62:67–74 (Ib)CrossRef
31.
Galor A, Jabs DA, Leder HA et al (2008) Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 115(10):1826–1832 (III)CrossRefPubMed
32.
33.
Garcês S, Demengeot J, Benito-Garcia E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72(12):1947–1955 (Ia)CrossRefPubMed
34.
Gaudio PA (2004) A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm 12:169–192 (IV)CrossRefPubMed
35.
Greenwood AJ, Stanford MR, Graham EM (1998) The role of azathioprine in the management of retinal vasculitis. Eye 12:783–788 (III)CrossRefPubMed
36.
Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111(3):491–500 (IIb)CrossRefPubMed
37.
Hatemi G, Silman A, Bang D et al (2009) Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 68:1528–1534 (II)CrossRefPubMed
38.
Hazirolan D, Pleyer U (2013) Think global-act local: intravitreal drug delivery systems in chronic noninfectious uveitis. Ophthalmic Res 49:59–65 (IV)CrossRefPubMed
39.
Heiligenhaus A, Thurau S, Hennig M et al (2010) Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol 248:1531–1551 (IV)CrossRefPubMed
40.
Heiligenhaus A, Breitbach M, Spital et al (2014) Posteriore Uveitis Teil 1: Diagnose und Grundkonzepte der Therapie. Klin Monbl Augenheilkd 231(4):457–469 (IV)CrossRefPubMed
41.
Heiligenhaus A, Breitbach M, Spital G et al (2014) Posteriore Uveitis. Teil 2: Die unterschiedlichen Krankheitsbilder. Klin Monbl Augenheilkd 231(5):555–579 (IV)CrossRefPubMed
42.
Hogan AC, McAvoy CE, Dick AD et al (2007) Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 114(5):1000–1006 (III)CrossRefPubMed
43.
Islam SM, Tabbara KF (2002) Causes of uveitis at the eye center in Saudi Arabia: a retrospective review. Ophthalmic Epidemiol 9:239–249CrossRefPubMed
44.
Jabs DA, Rosenbaum JT, Foster CS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492–513 (IIb)CrossRefPubMed
45.
Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–516 (IIb)CrossRefPubMed
46.
47.
Jakob E, Reuland MS, Mackensen F et al (2009) Uveitis subtypes in a German interdisciplinary uveitis center – analysis of 1916 patients. J Rheumatol 36(1):127–136 (III)PubMed
48.
49.
Kaplan-Messas A, Barkana Y, Avni I, Neumann R (2003) Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 11:131–139 (III)CrossRefPubMed
50.
Kempen JH, Gangaputra S, Daniel E et al (2008) Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 146:802–812 (Ib)CrossRefPubMedCentralPubMed
51.
Kempen JH, Van Natta ML, Altaweel MM et al (2015) Factors predicting visual acuity outcome in intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment (MUST) trial. Am J Ophthalmol 160(6):1133–1141 (Ib)CrossRefPubMedCentralPubMed
52.
53.
Lau CH, Comer M, Lightman S (2003) Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 31(6):487–491 (III)CrossRefPubMed
54.
Lerman A, Lewen MD, Kempen JH et al (2015) Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol 160:193–200 (IIb)CrossRefPubMedCentralPubMed
55.
Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121(3):785–796 (Ib)CrossRefPubMed
56.
Lowder C, Belfort R Jr., Lightman S et al (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129(5):545–553 (Ib)CrossRefPubMed
57.
Markomichelakis NN, Theodossiadis PG, Pantenelia E et al (2004) Infliximab for chronic macular edema associated with uveitis. Am J Ophthalmol 138:648–650 (IV)CrossRefPubMed
58.
Markomichelakis NN, Demicha E, Masselos S, Sfikakis PP (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol 154:534–541 (IV)CrossRefPubMed
59.
Masuda K, Nakajima A, Urayama A et al (1989) Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096 (Ib)CrossRefPubMed
60.
Mochizuki M, Masuda K, Sakane T et al (1993) A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 115:763–769 (IIa)CrossRefPubMed
61.
Murphy CC, Greiner K, Plskova J et al (2005) Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 123(5):634–641 (Ib)CrossRefPubMed
62.
Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. https://​doi.​org/​10.​1016/​S0140-6736(16)31339-3
63.
Nussenblatt RB, Palestine AG, Chan CC et al (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92(4):467–471 (Ib)CrossRefPubMed
64.
Nussenblatt RB, Palestine AG, Chan CC et al (1991) Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 112(2):138–146 (Ib)CrossRefPubMed
65.
Ozyazgan Y, Yurdakul S, Yazici H et al (1992) Low dose cyclosporin a versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol 76:241–243 (IIa)CrossRefPubMedCentralPubMed
66.
Patel AK, Newcomb CW, Liesegang TL et al (2016) Risk of retinal neovascularization in cases of uveitis. Ophthalmology 123:646–654 (IIb)CrossRefPubMed
67.
Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV (2008) Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm 16:161–165 (III)CrossRefPubMed
68.
Pleyer U, Stübiger N (2014) New pharmacotherapy options for noninfectious posterior uveitis. Expert Opin Biol Ther 14:1783–1799 (IV)CrossRefPubMed
69.
70.
Pleyer U, Pohlmann D, Stübiger N (2016) Therapie der posterioren, nichtinfektiösen Uveitis – aktueller Stand und künftige Entwicklungen. Ophthalmologe 113:380–390 (IV)CrossRefPubMed
71.
72.
Rathinam SR, Babu M, Thundikandy R et al (2014) A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology 121:1863–1870 (Ib)CrossRefPubMedCentralPubMed
73.
74.
Roesel M, Gutfleisch M, Heinz C et al (2009) Intravitreal and orbital floor triamcinolone acetonide injections in non-infectious uveitis. A comparative study. Ophthalmic Res 42:81–86 (III)CrossRefPubMed
75.
Roy M (2007) Early clinical experience with leflunomide in uveitis. Can J Ophthalmol 42(4):634 (III)CrossRefPubMed
76.
Samson CM, Waheed N, Baltatzis S, Foster CS (2001) Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108:1134–1139 (III)CrossRefPubMed
77.
Santos-Gomez M, Calvo-Rio V, Blanco R et al (2016) The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behcet’s disease: results of a multicentre open-label study. Clin Exp Rheumatol 34(6 Suppl 102):S34–S40 (IV)PubMed
78.
Schaap-Fogler M, Amer R, Friling R et al (2014) Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol 252(4):633–640 (III)CrossRefPubMed
79.
Schilling H, Heiligenhaus A, Laube T et al (2005) Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 25(2):182–188 (III)CrossRefPubMed
80.
Siepmann K, Huber M, Stubiger N et al (2006) Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 244(7):788–794 (III)CrossRefPubMed
81.
Suhler EB, Smith JR, Giles TR et al (2009) Infliximab therapy for refractory uveitis: 2‑year results of a prospective trial [letter. Arch Ophthalmol 127:819–822 (Ib)PubMed
82.
Suhler EB, Lowder CY, Goldstein DA et al (2013) Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 97:481–486 (Ib)CrossRefPubMed
83.
Takeuchi M, Kezuka T, Sugita S et al (2014) Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology 121:1877–1884 (IIb)CrossRefPubMed
84.
Taylor SR, Banker A, Schlaen A et al (2013) Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina 33:2149–2154 (III)CrossRefPubMed
85.
86.
The Multicenter Uveitis Steroid Treatment (MUST), Trial Follow-up Study Research Group (2015) Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis. Fifty-four-month results of the Multicenter Uveitis Steroid Treatment (MUST) trail and follow-up study. Ophthalmology 122:1967–1975 (Ib)CrossRef
87.
The Multicenter Uveitis Steroid Treatment (MUST), Trial Follow-up Study Research Group (2015) Quality of life and risks associated with systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 122:1976–1986 (Ib)CrossRef
88.
Thomas SS, Borazan N, Barroso N et al (2015) Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 29(4):241–258 (Ia)CrossRefPubMed
89.
Thorne JE, Jabs DA, Qazi FA et al (2005) Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112:1472–1477 (III)CrossRefPubMed
90.
Thorne JE, Skup M, Tundia N et al (2016) Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Acta Ophthalmol 94:331–339CrossRef
91.
Udeotuk JD, Dai Y, Ying GS et al (2012) Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Ophthalmology 119:1569–1574 (IIb)CrossRef
92.
Yates WB, Yajdic CM, Na R et al (2015) Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study. Ophthalmology 122:265–273 (IIb)CrossRefPubMed
93.
Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 322:281–285 (Ib)CrossRefPubMed
Metadaten
Titel
Leitlinie Nr. 24b der DOG und BVA
Nichtinfektiöse Uveitis posterior
verfasst von
Deutsche Ophthalmologische Gesellschaft
Berufsverband der Augenärzte Deutschlands e. V.
Publikationsdatum
20.11.2017
Verlag
Springer Medizin
Schlagwörter
EBM
Uveitis
Erschienen in
Die Ophthalmologie / Ausgabe 12/2017
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI
https://doi.org/10.1007/s00347-017-0582-z

Weitere Artikel der Ausgabe 12/2017

Die Ophthalmologie 12/2017 Zur Ausgabe

Kasuistiken

Zwei Kinder mit intermediärer Uveitis und Granuloma anulare in derselben Nachbarschaft

Bild und Fall

Akute unilaterale Sehstörung einer 26-jährigen gesunden Frau

CME

Kindliches Hämangiom im Lidbereich

Kasuistiken

Vogt-Koyanagi-Harada-Syndrom

Übersichten

Bewertung des Zusatznutzens neuer Ophthalmika

In eigener Sache

Dank an die Gutachter 2017

Abrechnung: Die aktuellen Änderungen im Blick

Ob EBM, GOÄ, UV-GOÄ oder GOP: Die Abrechnungsdatenbank ist mit allen Gebührenordnungen stets auf dem neuesten Stand und wird kontinuierlich mit Kommentaren, Tipps und aktuellen Urteilen versehen.
Mit dem SpringerMedizin.de-Zugang können Sie die Abrechnungsdatenbank in vollem Umfang nutzen.

Informieren Sie sich jetzt!
Bildnachweise